Pharmaceutical

China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.

Aug 15, 2024 - 04:00
China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.
Read the original article

Tags:

Previous Article

UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease

Next Article

Eli Lilly inaugurates R&D facility in Boston, US

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Mar 13, 2024

STAT+: Could kidney transplant patients be spared a lifetime of immunosuppressants?

STAT+: Could kidney transplant patients be spared a lif...

Nov 3, 2023

LCRF, Daiichi Sankyo and AstraZeneca enter research collaboration

LCRF, Daiichi Sankyo and AstraZeneca enter research col...

Mar 19, 2023